Madrid-based pharmaceutical group Zeltia has reported strong results for the year ending 31 December 2010.
The group’s net revenues for 2010 totalled €153.5 million, a rise of 24.4 per cent from 2009, when revenues were €123.4 million. Zeltia said the increase was largely due to a 70 per cent growth in sales of Yondelis, Spain’s first anti-tumour drug.
At year-end, Yondelis had been approved for sale in 63 countries, 33 of which are outside the European Economic Area.
EBITDA rose by 74 per cent in 2010, with net income attributable to the parent company rising by 71.6 per cent.
Net sales for 2010 in the group’s biopharmaceutical business were €79.4 million—up from €51.1 million in 2009—of which €72.1 million was attributable to Yondelis. Biopharmaceuticals accounted for 52 per cent of total group revenues in 2010, outpacing for the first time revenues from the group’s consumer chemicals business, which totalled €73.2 million.
Zeltia also reported that R&D expenditure increased by 4.37 per cent year-on-year, with a total €55.6 million being spent on R&D in 2010.
Madrid-based Zeltia specialises in the development of marine-based drugs for treating tumours and central nervous system illnesses. The group operates in both the biopharmaceutical sector and consumer chemicals sector.
Research fields within the group’s biopharmaceutical business include oncology, the central nervous system, molecular diagnostics and genetic identification and RNAi (RNA interference).
The group’s consumer chemicals segment is involved in the manufacture and sale of products for home care and paints, as well as protective timber coatings for professionals and the DIY market.
